Advanced Enzyme Technologies Limited
Financial trend (92/100) does the heavy lifting; momentum (20/100) is the drag.
Fair valueOur blended model reads Advanced Enzyme Technologies Limited as a Hold at 57/100. We put fair value near ₹241.79; at ₹315.1 that leaves roughly 23% downside, so the stock screens overvalued by 23%. On 21.1x trailing earnings it sits roughly in line with the Basic Materials median of about 22.2x. The price is about 19% below its 52-week high of ₹390.42 and 24% above the low of ₹254.2. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹370 implies about 17% upside across 1 analysts. It clears 7 of 13 investability checks, with durability 82, valuation 57 and momentum 20 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹193.43.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-19.29% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold57Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 11.0%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 22%
- Pass: Earnings growing: 62%
- Pass: Net margin ≥ 10%: 22.6%
- Pass: Current ratio > 1.5: 9.78
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 15.68
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter55.5%
- Institutions18.6%
- Public & other25.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (22.6%).
- Financially solid — Altman Z 15.68.
Opportunities
- Earnings growing (62% YoY).
- Revenue growing (22% YoY).
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Trades ~23% above our estimated fair value.
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited researches, develops, manufactures, and markets enzymes and probiotics across India, Europe, the United States, Asia, and internationally. The company supplies enzyme and probiotic-based nutritional supplements for human healthcare and nutrition, animal nutrition, and industrial applications including fruit and vegetable processing, baking, brewing, malting, starch and grain processing, protein modification, and yeast processing.
Advanced Enzyme Technologies Limited — frequently asked questions
Is Advanced Enzyme Technologies Limited a buy, hold or sell?
StocksWizard currently rates Advanced Enzyme Technologies Limited (ADVENZYMES) a Hold, based on a blended score of 57/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Advanced Enzyme Technologies Limited's fair value?
Our blended DCF and relative-valuation model estimates Advanced Enzyme Technologies Limited's fair value at about ₹241.79, versus a current price of ₹315.1 — roughly 23% downside. On that basis the stock looks overvalued by 23%.
Is Advanced Enzyme Technologies Limited financially healthy?
Advanced Enzyme Technologies Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Advanced Enzyme Technologies Limited's share price performed?
Advanced Enzyme Technologies Limited is down 12% over three months, and last traded at ₹315.1. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.